查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2056377

月經症候群（PMS）治療市場報告：按藥物類型、通路和地區分類（2026-2034 年）

Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 136 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球月經症候群（PMS）治療市場規模達14.899億美元。預計從2026年到2034年，該市場將以3.09%的複合年成長率成長，到2034年達到19.765億美元。推動該市場成長的因素包括：人們對精準醫療的日益關注，以期改善患者預後和提高治療效率；醫療保健支出不斷增加，以改善醫療服務可及性並擴大治療選擇；以及女性勞動參與率的提高。

月經症候群（PMS）治療市場趨勢：

人們越來越關注精準醫療。

根據出版商報告顯示，2023年全球精準醫療市場規模達752億美元。精準醫療能夠根據患者的基因譜、荷爾蒙水平和症狀等特徵，提供量身定做的醫療幹預措施。以經月經症候群（PMS）為例，其症狀和嚴重程度因人而異，因此個人化治療方案能夠提供更有針對性、更有效的治療。此外，透過利用與PMS相關的遺傳因素和生物標記，可以為每位患者量身定做最有效的治療方法。這有助於改善治療效果，並減少治療方法的試驗誤。此外，基於患者的基因或生理特徵進行治療方法，可以選擇副作用風險較低的藥物，這也是推動市場成長的因素之一。

醫療保健成本不斷上漲

隨著醫療保健支出增加，包括患有經前症候群 (PMS) 的女性在內的更多人群能夠獲得基層醫療醫生、婦科醫生和其他醫療保健專業人員的診療，從而得到正確的診斷和治療。此外，高額的醫療保健支出通常也意味著更多人能夠獲得其他 PMS 治療方案，包括荷爾蒙療法和抗憂鬱症等藥物療法，以及認知行為療法和生活方式調整等非藥物療法。不斷上漲的醫療保健成本也為研發活動創造了更多機會，並有望開發出更好的 PMS治療方法。根據美國醫療保險和醫療補助服務中心 (CMS) 網站 2024 年更新的信息，醫療保健支出佔 GDP 的比例預計將從 2022 年的 17.3% 成長到 2032 年的 19.7%。

女性勞動參與率的提高

根據世界銀行的數據，2023年全球女性勞動參與率為49%。隨著越來越多的女性進入勞動市場，經前症候群（PMS）的經濟影響日益顯著。其症狀會對生產力、出勤率和職場表現產生負面影響。鑑於這些影響，雇主和醫療保健機構越來越積極地尋找能夠減輕PMS對職場影響的有效治療方法。此外，企業正在投資於包含PMS等生殖健康議題支持職場健康計畫。這些計劃提供治療途徑、針對症狀易發日的靈活工作安排以及教育資源，所有這些都有助於提高人們對PMS治療方法的認知和使用。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球月經症候群（PMS）治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依藥物類型分類

  • 止痛藥
  • 抗憂鬱症
  • 口服避孕藥和卵巢抑制劑
  • 其他

第7章 市場區隔：依類型

  • 處方
  • 非處方藥

第8章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 藥局和零售藥房
  • 網路商店

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • AbbVie Inc.
    • BASF SE
    • Bayer AG
    • Dr. Reddy's Laboratories Ltd
    • Eli Lilly and Company
    • GlaxoSmithKline Plc.
    • H. Lundbeck A/S
    • Pfizer Inc.
    • SHIONOGI & Co. Ltd.
Product Code: SR112026A4284

The global premenstrual syndrome treatment market size reached USD 1,489.9 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 1,976.5 Million by 2034, exhibiting a growth rate (CAGR) of 3.09% during 2026-2034. The market is driven by the growing focus on precision medicine, as it enhances patient outcomes and treatment efficiency, rising healthcare spending, which improves access to care and expands treatment options, and increasing female workforce participation.

Premenstrual Syndrome Treatment Market Trends:

Growing focus on precision medicine

As per the publisher's report, the global precision medicine market reached US$ 75.2 Billion in 2023. Precision medicine can deliver medical interventions that are tailored as per patient characteristics including genetic profile, hormone status, and symptoms. In the context of PMS, it can vary widely in terms of symptoms and severity among individuals, personalized approaches allow for more targeted and effective treatments. Furthermore, genetic factors or biomarkers that are linked to PMS help in tailoring treatment options to be most effective for each patient. This is leading to improved outcomes and lesser trial and error in treatment options. Apart from this, by selecting medications that are less likely to cause an adverse reaction by matching patients with treatments based on their genetic or physiological profiles is expanding the market growth.

Rising healthcare spending

As healthcare expenditure is increasing, more people, including women troubled with PMS, are able to seek medical help, including primary care physicians, gynecologists and other practitioners who may diagnose and treat PMS appropriately. In addition, high healthcare spending often found to be associated with higher access to other treatment options of PMS, which includes pharmacological treatment like hormonal therapies, antidepressants, and non-pharmacological therapies like cognitive behavioral therapy or lifestyle modifications. High healthcare expenditure is creating more opportunities for R&D activities that can help find better PMS therapies. According to the content updated in 2024 on the website of the Centers for Medicare & Medicaid Services, the healthcare spending share of GDP is forecasted to grow from 17.3% in 2022 to 19.7% in 2032.

Increasing female workforce participation

As per the World Bank, female labor force participation rates were 49% worldwide in 2023. As more women are entering the workforce, the economic implications of PMS are becoming more apparent. This poses a threat to productivity, attendance and performance at work due to its symptoms. Recognizing these impacts, employers and healthcare providers are more motivated to find effective treatments that can help reduce the workplace disruptions caused by PMS. In addition, companies are investing in workplace wellness programs that include support for reproductive health issues like PMS. These programs offer access to therapies, flexible scheduling around symptomatic days, and educational resources, all of which increase awareness and use of available PMS treatments.

Premenstrual Syndrome Treatment Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on drug type, type, and distribution channel.

Breakup by Drug Type:

  • Analgesics
  • Antidepressants
  • Oral Contraceptives and Ovarian Suppression Agents
  • Others

Analgesics accounts for the majority of the market share

Premenstrual syndrome refers to several symptoms that are physical and psychological in nature and which affect many women prior to menstrual cycles, such as abdominal pain, headaches, and muscular pain. Analgesics are widely preferred as they provide quick relief from these symptoms, making them a go-to choose for many women looking immediate comfort during their menstrual cycles. In addition, people are getting aware about their efficiency in controlling pain, which is driving the demand for analgesics in the PMS treatment market.

Breakup by Type:

  • Prescription
  • Over-the-Counter

Over-the-counter holds the largest share of the industry

Over-the-counter (OTC) products for PMS include pain relievers, diuretics, and other supplements like calcium and magnesium that one can be purchased on the counter without the prescription of doctor. This accessibility allows women treat symptoms independently without having to see a doctor. Bloating, cramping, fatigue, and mood swings are becoming serious problems as a result of PMS. OTC medicines offer numerous solutions to these issues as per different symptoms. The familiarity of OTC brands and the ease of purchasing these products from pharmacies, retail stores, and online platforms is contributing to the market growth.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Stores

Drugs stores and retail pharmacies represent the leading market segment

Women are preferring drug stores and pharmacies as they can get a wide range of OTC medications and supplements to alleviate PMS symptoms. This ensures that those women suffering from PMS can get relief in the quickest way possible without the need for a prescription. . Secondly, drug stores and retail pharmacies offer customers a wide diversity of brands and forms of products which can help them select the required products according to their needs and symptoms. This variety enhances individual satisfaction and ensures that people can find products tailored as per their specific needs.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest premenstrual syndrome treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for premenstrual syndrome treatment.

As per an article published on the website of Canadian Institute for Health Information, Canada health care spending reached $344 billion in 2023. As healthcare expenditures is rising, there is a corresponding increase in the availability of specialized healthcare services and resources dedicated to the health of women, including PMS. This includes improved access to healthcare professionals who can diagnose and treat PMS effectively, leading to greater awareness and recognition of the condition among patients. Moreover, North America has a high prevalence of PMS cases, which prompts a significant demand for effective treatment solutions. In addition, the strong economy of the region, leading to the greater affordability of healthcare services and medications, further driving the market growth.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the premenstrual syndrome treatment industry include AbbVie Inc., BASF SE, Bayer AG, Dr. Reddy's Laboratories Ltd, Eli Lilly and Company, GlaxoSmithKline Plc., H. Lundbeck A/S, Pfizer Inc. and SHIONOGI & Co. Ltd.
  • Key players are developing and introducing new medications and treatments for managing PMS symptoms, expanding treatment choices for patients. They are conducting research and participating in clinical trials to better understand PMS mechanisms, validate treatment efficacy, and explore new therapeutic approaches. Moreover, many companies are focusing on personalized medicine approaches to tailor treatments based on individual patient characteristics, improving treatment outcomes and patient satisfaction. Key players are involved in advocacy efforts to raise awareness about PMS, improve diagnosis rates, and educate healthcare providers and patients about available treatment options. They are focusing on integrating digital health technologies, such as apps for symptom tracking, wearable devices, and telemedicine solutions, to enhance patient care and treatment outcome. For instance, in 2024, Samphire Neuroscience startup raised $2.3M to tackle PMS and period pain using neurotechnology wearable.

Key Questions Answered in This Report

  • 1.What was the size of the global premenstrual syndrome treatment market in 2025?
  • 2.What is the expected growth rate of the global premenstrual syndrome treatment market during 2026-2034?
  • 3.What are the key factors driving the global premenstrual syndrome treatment market?
  • 4.What has been the impact of COVID-19 on the global premenstrual syndrome treatment market?
  • 5.What is the breakup of the global premenstrual syndrome treatment market based on the drug type?
  • 6.What is the breakup of the global premenstrual syndrome treatment market based on the type?
  • 7.What is the breakup of the global premenstrual syndrome treatment market based on the distribution channel?
  • 8.What are the key regions in the global premenstrual syndrome treatment market?
  • 9.Who are the key players/companies in the global premenstrual syndrome treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Premenstrual Syndrome Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Analgesics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Antidepressants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Oral Contraceptives and Ovarian Suppression Agents
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Type

  • 7.1 Prescription
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Over-the-Counter
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Drug Stores and Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 AbbVie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 BASF SE
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bayer AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Dr. Reddy's Laboratories Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Eli Lilly and Company
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 GlaxoSmithKline Plc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 H. Lundbeck A/S
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Pfizer Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SHIONOGI & Co. Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020-2025
  • Figure 2: Global: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 3: Global: Premenstrual Syndrome Treatment Market: Breakup by Drug Type (in %), 2025
  • Figure 4: Global: Premenstrual Syndrome Treatment Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Premenstrual Syndrome Treatment Market: Breakup by Distribution Channel (in %), 2025
  • Figure 6: Global: Premenstrual Syndrome Treatment Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Premenstrual Syndrome Treatment (Analgesics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 8: Global: Premenstrual Syndrome Treatment (Analgesics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 9: Global: Premenstrual Syndrome Treatment (Antidepressants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Premenstrual Syndrome Treatment (Antidepressants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Premenstrual Syndrome Treatment (Oral Contraceptives and Ovarian Suppression Agents) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Premenstrual Syndrome Treatment (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Premenstrual Syndrome Treatment (Prescription) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Premenstrual Syndrome Treatment (Prescription) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Premenstrual Syndrome Treatment (Over-the-Counter) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Premenstrual Syndrome Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Premenstrual Syndrome Treatment (Drug Stores and Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Premenstrual Syndrome Treatment (Online Stores) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Premenstrual Syndrome Treatment (Online Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: North America: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: North America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: United States: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: United States: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: Canada: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: Canada: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: Asia-Pacific: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: Asia-Pacific: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: China: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: China: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Japan: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Japan: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: India: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: India: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: South Korea: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: South Korea: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: Australia: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: Australia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: Indonesia: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: Indonesia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Europe: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Europe: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Germany: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Germany: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: France: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: France: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: United Kingdom: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: United Kingdom: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: Italy: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: Italy: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: Spain: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: Spain: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Russia: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Russia: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Latin America: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Latin America: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Brazil: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Brazil: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Mexico: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Mexico: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Others: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Others: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Middle East and Africa: Premenstrual Syndrome Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Middle East and Africa: Premenstrual Syndrome Treatment Market: Breakup by Country (in %), 2025
  • Figure 73: Middle East and Africa: Premenstrual Syndrome Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Global: Premenstrual Syndrome Treatment Industry: SWOT Analysis
  • Figure 75: Global: Premenstrual Syndrome Treatment Industry: Value Chain Analysis
  • Figure 76: Global: Premenstrual Syndrome Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Premenstrual Syndrome Treatment Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 3: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 4: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 5: Global: Premenstrual Syndrome Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Premenstrual Syndrome Treatment Market: Competitive Structure
  • Table 7: Global: Premenstrual Syndrome Treatment Market: Key Players